Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Nov;18(5):749–758. doi: 10.1111/j.1365-2125.1984.tb02538.x

Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients.

J F Giudicelli, M Chaignon, C Richer, B Giroux, J Guedon
PMCID: PMC1463539  PMID: 6095887

Abstract

The pharmacokinetic parameters of unchanged plasma captopril and the kinetics of the drug effects on plasma converting enzyme activity (PCEA), plasma renin activity (PRA), plasma aldosterone (PA) and mean blood pressure (MBP) were studied over 24 h after oral administration in three groups of hypertensive patients: with normal renal function (group 1, plasma creatinine less than 110 mumol/l, n = 10), with moderate chronic renal failure (group 2, 135 less than plasma creatinine less than 450 mumol/l, n = 10) and with severe chronic renal failure (group 3, plasma creatinine greater than 500 mumol/l, n = 10). Renal impairment had no effect on plasma captopril Cmax, CLtot and relative bioavailability (AUC). In contrast, captopril kel decreased while T1/2 increased progressively from group 1 to group 3. PCEA blockade (T1/2 and AUC) was increased significantly and proportionally to the degree of renal impairment. However, there were no differences between the three groups regarding captopril-induced modifications of PRA and PA. Although the maximal reduction in MBP was identical in the three groups, the overall antihypertensive effect (AUC) of captopril increased significantly and progressively from group 1 to group 3, especially in duration. There was no correlation between basal plasma creatinine values and unchanged captopril relative bioavailability (AUC) and between unchanged captopril relative bioavailability (AUC) and the drug effects (AUC) on PCEA, PRA, PA and MBP. However there was a correlation between basal plasma creatinine values and plasma captopril T1/2, PCEA blockade (AUC) and overall antihypertensive effect (AUC). The apparent discrepancy between the lack of effects of chronic renal failure on plasma unchanged captopril bioavailability and its potentiating effects on PCEA blockade and MBP reduction may be accounted for by the renal impairment-induced accumulation of captopril metabolites.

Full text

PDF
749

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Awan N. A., Evenson M. K., Needham K. E., Win A., Mason D. T. Efficacy of oral angiotensin-converting enzyme inhibition with captopril therapy in severe chronic normotensive congestive heart failure. Am Heart J. 1981 Jan;101(1):22–31. doi: 10.1016/0002-8703(81)90379-3. [DOI] [PubMed] [Google Scholar]
  2. Bianchetti G., Graziani G., Brancaccio D., Morganti A., Leonetti G., Manfrin M., Sega R., Gomeni R., Ponticelli C., Morselli P. L. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet. 1976;1(5):373–384. doi: 10.2165/00003088-197601050-00004. [DOI] [PubMed] [Google Scholar]
  3. Campbell B. C., Shepherd A. N., Elliott H. L., McLean K., Reid J. L. Prolonged converting enzyme inhibition following captopril in patients with renal insuffficiency. Br J Clin Pharmacol. 1982 May;13(5):755–757. doi: 10.1111/j.1365-2125.1982.tb01455.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Campbell B. C., Shepherd A. N., Reid J. L. Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension. Br J Clin Pharmacol. 1982 Feb;13(2):213–217. doi: 10.1111/j.1365-2125.1982.tb01359.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Duchin K. L., Singhvi S. M., Willard D. A., Migdalof B. H., McKinstry D. N. Captopril kinetics. Clin Pharmacol Ther. 1982 Apr;31(4):452–458. doi: 10.1038/clpt.1982.59. [DOI] [PubMed] [Google Scholar]
  6. Gavras H., Biollaz J., Waeber B., Brunner H. R., Gavras I., Davies R. O. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet. 1981 Sep 12;2(8246):543–547. doi: 10.1016/s0140-6736(81)90937-5. [DOI] [PubMed] [Google Scholar]
  7. Heel R. C., Brogden R. N., Speight T. M., Avery G. S. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs. 1980 Dec;20(6):409–452. doi: 10.2165/00003495-198020060-00001. [DOI] [PubMed] [Google Scholar]
  8. Imbs J. L., Bakish D., Schmidt M., Schwartz J. Low temperature sustains inhibition of angiotensin-converting-enzyme activity in serum from patients taking captopril. N Engl J Med. 1981 Jul 23;305(4):229–229. doi: 10.1056/NEJM198107233050425. [DOI] [PubMed] [Google Scholar]
  9. Jarrott B., Anderson A., Hooper R., Louis W. J. High-performance liquid chromatographic analysis of captopril in plasma. J Pharm Sci. 1981 Jun;70(6):665–667. doi: 10.1002/jps.2600700622. [DOI] [PubMed] [Google Scholar]
  10. Jarrott B., Drummer O., Hooper R., Anderson A. I., Miach P. J., Louis W. J. Pharmacokinetic properties of captopril after acute and chronic administration to hypertensive subjects. Am J Cardiol. 1982 Apr 21;49(6):1547–1549. doi: 10.1016/0002-9149(82)90385-x. [DOI] [PubMed] [Google Scholar]
  11. Kawahara Y., Hisaoka M., Yamazaki Y., Inage A., Morioka T. Determination of captopril in blood and urine by high-performance liquid chromatography. Chem Pharm Bull (Tokyo) 1981 Jan;29(1):150–157. doi: 10.1248/cpb.29.150. [DOI] [PubMed] [Google Scholar]
  12. Kripalani K. J., McKinstry D. N., Singhvi S. M., Willard D. A., Vukovich R. A., Migdalof B. H. Disposition of captopril in normal subjects. Clin Pharmacol Ther. 1980 May;27(5):636–641. doi: 10.1038/clpt.1980.90. [DOI] [PubMed] [Google Scholar]
  13. Onoyama K., Hirakata H., Iseki K., Fujimi S., Omae T., Kobayashi M., Kawahara Y. Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure. Hypertension. 1981 Jul-Aug;3(4):456–459. doi: 10.1161/01.hyp.3.4.456. [DOI] [PubMed] [Google Scholar]
  14. Pham-Huu-Trung M. T., Corvol P. A direct determination of plasma aldosterone. Steroids. 1974 Nov;24(5):587–508. doi: 10.1016/0039-128x(74)90013-0. [DOI] [PubMed] [Google Scholar]
  15. Reidenberg M. M., Odar-Cederlöf I., von Bahr C., Borgå O., Sjöqvist F. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med. 1971 Jul 29;285(5):264–267. doi: 10.1056/NEJM197107292850506. [DOI] [PubMed] [Google Scholar]
  16. Richer C., Giroux B., Plouin P. F., Maarek B., Giudicelli J. F. Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. Br J Clin Pharmacol. 1984 Mar;17(3):243–250. doi: 10.1111/j.1365-2125.1984.tb02338.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Roulston J. E., MacGregor G. A. The measurement of angiotensin-converting enzyme in subjects receiving captopril. N Engl J Med. 1980 Aug 14;303(7):397–397. doi: 10.1056/NEJM198008143030717. [DOI] [PubMed] [Google Scholar]
  18. Waeber B., Brunner H. R., Brunner D. B., Curtet A. L., Turini G. A., Gavras H. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension. 1980 Mar-Apr;2(2):236–242. doi: 10.1161/01.hyp.2.2.236. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES